• Sandra L Bixler, Thomas M Bocan, Jay Wells, Kelly S Wetzel, Sean A Van Tongeren, Lian Dong, Nicole L Garza, Ginger Donnelly, Lisa H Cazares, Jonathan Nuss, Veronica Soloveva, Keith A Koistinen, Lisa Welch, Carol Epstein, Li-Fang Liang, Dennis Giesing, Robert Lenk, Sina Bavari, and Travis K Warren.
• US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Ft. Detrick, MD 21702, USA.
• Antiviral Res. 2018 Mar 1; 151: 97-104.

AbstractFavipiravir is a broad-spectrum antiviral agent that has demonstrated efficacy against Ebola virus (EBOV) in rodents. However, there are no published reports of favipiravir efficacy for filovirus infection of nonhuman primates (NHPs). Here we evaluated the pharmacokinetic profile of favipiravir in NHPs, as well as in vivo efficacy against two filoviruses, EBOV and Marburg virus (MARV). While no survival benefit was observed in two studies employing once- or twice-daily oral dosing of favipiravir during EBOV infection of NHPs, an antiviral effect was observed in terms of extended time-to-death and reduced levels of viral RNA. However, oral dosing in biosafety level-4 (BSL-4) presents logistical and technical challenges, and repeated anesthesia events may potentially worsen survival outcome in animals. For the third study of treatment of MARV infection, we therefore made use of catheters, jackets, and tethers for intravenous (IV) dosing and blood collection, which minimized the requirement for repeated anesthesia events. When MARV infection was treated with IV favipiravir, five of six animals (83%) survived infection, while all untreated NHPs succumbed. An accompanying report presents the results of favipiravir treatment of EBOV infection in mice.Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

42 keywords...

hide…